



## OPEN ACCESS

EDITED AND REVIEWED BY  
Avichai Shimoni,  
Sheba Medical Center, Israel

## \*CORRESPONDENCE

Alex H. Chang

✉ changah@yakebiotech.com

Yi Su

✉ suhang1234@hotmail.com

Jin Rao

✉ raojin720325@163.com

<sup>†</sup>These authors have contributed  
equally to this work

RECEIVED 28 July 2025

ACCEPTED 14 August 2025

PUBLISHED 22 August 2025

## CITATION

Zou Z, Lai S, Yi H, Zhang Q, Yao H,  
Yang H, Zhang L, Chang AH, Su Y  
and Rao J (2025) Correction: Case Report:  
CAR-T therapy for primary cerebellar ALK-  
negative anaplastic large cell lymphoma.  
*Front. Immunol.* 16:1674954.  
doi: 10.3389/fimmu.2025.1674954

## COPYRIGHT

© 2025 Zou, Lai, Yi, Zhang, Yao, Yang, Zhang,  
Chang, Su and Rao. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma

Zhongqing Zou<sup>1†</sup>, Sihan Lai<sup>2†</sup>, Hai Yi<sup>2</sup>, Qian Zhang<sup>2</sup>, Hao Yao<sup>2</sup>,  
Hui Yang<sup>2</sup>, Ling Zhang<sup>2</sup>, Alex H. Chang<sup>3,4\*</sup>, Yi Su<sup>2\*</sup> and Jin Rao<sup>1\*</sup>

<sup>1</sup>Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, China, <sup>2</sup>Department of Hematology, The General Hospital of Western Theater Command, Sichuan Clinical Research Center for Hematological Disease, Branch of National Clinical Research Center for Hematological Disease, Chengdu, China, <sup>3</sup>Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China, <sup>4</sup>Shanghai YaKe Biotechnology Ltd., Shanghai, China

## KEYWORDS

primary central nervous system lymphoma (PCNSL), T-cell lymphoma, cerebellar, ALK, ALCL, CAR-T, CD30, CD7

## A Correction on

## Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma

By Zou Z, Lai S, Yi H, Zhang Q, Yao H, Yang H, Zhang L, Chang AH, Su Y and Rao J (2025) *Front. Immunol.* 16:1570214. doi: 10.3389/fimmu.2025.1570214

File **Table 1** was erroneously published with the original version of this paper. The file has now been removed.

The original version of this article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.